Granules India Ltd-$

Granules India Ltd-$

Granules India Limited announced that it has submitted a Paragraph IV certification in connection with its ANDA for Ruxolitinib Extended-Release Tablets, and believes it is eligible for first-to-file status for the product.

Granules India Ltd-$

Granules India Ltd held a webinar to discuss its growth strategy and transformation plans, highlighting four growth engines: control substances, complex generics and early market opportunities, oncologies, and peptide CDMO. The company aims to translate investments into a larger business with faster earnings growth over the next three to four years while maintaining financial discipline.

Granules India Ltd-$

Granules India Ltd has incorporated a wholly owned foreign subsidiary, TRITON FARMACEUTICA DO BRASIL LTDA, in Brazil. The subsidiary is in the pharmaceuticals industry and will manufacture, promote, and distribute pharmaceuticals and related products. The acquisition is under the automatic route and does not require any cash consideration or share swap.

Granules India Ltd-$

Granules India Ltd has uploaded the audio recording of its webinar held on September 29, 2026, on its website.

Granules India Ltd-$

Granules India Ltd has announced a webinar on September 29, 2026, to discuss its transformation journey, focusing on growth engines such as controlled substances, complex formulations, oncology, and peptide CDMO.

Granules India Ltd-$

Granules India Ltd has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, indicating a change in shareholding by Uma Devi Chigurupati, a promoter group member, who has acquired 2,48,80,342 shares, increasing her holding to 12.51%.

Granules India Ltd-$

Granules India Ltd has announced the closure of its trading window for insiders, including designated persons and their immediate relatives, from October 1, 2026, until 48 hours after the declaration of unaudited financial results for the second quarter and half-year ended September 30, 2026.

Granules India Ltd-$

Granules India Ltd has announced a schedule for an analyst/investor meeting on September 28, 2026, in New Delhi, without sharing any unpublished price-sensitive information.

Granules India Ltd-$

Granules India Ltd has allotted 2,49,82,906 equity shares to the members of the Promoter Group upon conversion of warrants, increasing the paid-up equity share capital from Rs.24,77,96,921 to Rs.27,27,79,827 and Rs. 27,27,96,921 on diluted basis.

Granules India Ltd-$

Granules India Ltd has received the balance subscription amount of Rs. 1,093 crores from the promoter group, making 2,49,14,530 warrants eligible for conversion into equity shares. This has strengthened the company's net cash position and enhanced its flexibility to pursue growth initiatives.

Granules India Ltd-$

Granules India Ltd has announced the internal transfer of Mr. Sanjay Kumar, Chief Strategy Officer, to its wholly owned subsidiary Ascelis Peptides Private Limited, effective August 13, 2026.

Granules India Ltd-$

Granules India Ltd. held its 35th Annual General Meeting (AGM) on August 6, 2026, through video conferencing. The meeting was attended by 67 members, including directors and representatives. The AGM adopted the standalone and consolidated audited financial statements for FY 2025-26, declared a final dividend of Rs. 1.75 per equity share, and re-appointed Ms. Priyanka Chigurupati as a director. The Scrutinizer's report on remote e-voting and voting results was also presented.

Granules India Ltd-$

Granules India Ltd held its 35th Annual General Meeting on August 6, 2026, through video conferencing, with 67 members in attendance. The meeting adopted the standalone and consolidated audited financial statements for FY 2025-26, declared a final dividend of Rs. 1.75 paise per equity share, and re-appointed Ms. Priyanka Chigurupati as a director.

Granules India Ltd-$

Granules India Ltd has received a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 from Life Insurance Corporation of India.

Granules India Ltd-$

Granules India Ltd reported its Q1 FY27 earnings, with revenue growing 22% YoY to INR1,477 crores, gross margin at 65.6%, EBITDA growing 37% to INR339 crores, and profit after tax growing 60% to INR180 crores. The company's return on capital improved to 18% and net debt to EBITDA is 0.07x, making it debt-free for practical purposes.

Granules India Ltd-$

Granules India Ltd has announced the audio recording of its investor call for FY27 earnings conference. The recording is available on the company's website.

Granules India Ltd-$

Granules India Ltd has submitted a Monitoring Agency Report for the quarter ended June 30, 2026, as required by SEBI regulations, detailing the utilization of proceeds from a Preferential Issue.

Granules India Ltd-$

Granules India Ltd has reported a 22% YoY growth in revenue to ₹14,768 Mn, with PAT increasing by 60% YoY to ₹1,800 Mn and EBITDA by 37% YoY to ₹3,389 Mn. The company's Complex Gx mix has increased to 50% of its FD portfolio, lifting gross margin to 65.6% and EBITDA margin to 22.9% (+256 bps YoY). Net Debt/EBITDA has improved to 0.07x from 0.34x, and ROCE has increased to 18.0% (+196 bps YoY) on ₹3,874 Mn cash flow from operations.

Granules India Ltd-$

Granules India Ltd. has announced its Q1FY27 financial results, with revenue from operations at INR 14,768 Mn, up 22% YoY, EBITDA at INR 3,389 Mn, up 37% YoY, PBT before Exceptional Item at INR 2,404 Mn, up 41% YoY, and PAT at INR 1,800 Mn, up 60% YoY.

Granules India Ltd-$

Granules India Ltd has announced its unaudited financial results for the first quarter ended June 30, 2026, with revenue from operations at ₹8,018.77 crore and a net profit of ₹8,156.61 crore.